FR13C0028I2 - Polypeptides chimeriques modifies a pharmacocinetique amelioree - Google Patents

Polypeptides chimeriques modifies a pharmacocinetique amelioree

Info

Publication number
FR13C0028I2
FR13C0028I2 FR13C0028C FR13C0028C FR13C0028I2 FR 13C0028 I2 FR13C0028 I2 FR 13C0028I2 FR 13C0028 C FR13C0028 C FR 13C0028C FR 13C0028 C FR13C0028 C FR 13C0028C FR 13C0028 I2 FR13C0028 I2 FR 13C0028I2
Authority
FR
France
Prior art keywords
modified polypeptides
enhanced pharmacokinetics
chimeric modified
pharmacokinetics
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0028C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of FR13C0028I1 publication Critical patent/FR13C0028I1/fr
Application granted granted Critical
Publication of FR13C0028I2 publication Critical patent/FR13C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
FR13C0028C 1999-06-08 2013-05-14 Polypeptides chimeriques modifies a pharmacocinetique amelioree Active FR13C0028I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
EP00932721A EP1183353B1 (fr) 1999-06-08 2000-05-23 Polypeptides chimeriques modifies a pharmacocinetique amelioree

Publications (2)

Publication Number Publication Date
FR13C0028I1 FR13C0028I1 (fr) 2013-06-14
FR13C0028I2 true FR13C0028I2 (fr) 2014-05-16

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0028C Active FR13C0028I2 (fr) 1999-06-08 2013-05-14 Polypeptides chimeriques modifies a pharmacocinetique amelioree

Country Status (33)

Country Link
EP (2) EP1183353B1 (fr)
JP (2) JP4723140B2 (fr)
KR (1) KR100659477B1 (fr)
CN (3) CN101433715B (fr)
AT (2) ATE417928T1 (fr)
AU (2) AU779303B2 (fr)
BE (1) BE2013C029I2 (fr)
BR (2) BR0011407A (fr)
CA (1) CA2376379C (fr)
CY (2) CY1108883T1 (fr)
CZ (2) CZ303656B6 (fr)
DE (2) DE60019415T2 (fr)
DK (2) DK1183353T3 (fr)
ES (2) ES2237429T3 (fr)
FR (1) FR13C0028I2 (fr)
HK (3) HK1043388A1 (fr)
HR (1) HRP20010908B1 (fr)
HU (3) HU229156B1 (fr)
IL (3) IL146890A0 (fr)
LT (1) LTC1183353I2 (fr)
LU (1) LU92195I2 (fr)
ME (2) MEP3208A (fr)
MX (1) MXPA01012630A (fr)
NO (3) NO330775B1 (fr)
NZ (1) NZ515913A (fr)
PL (1) PL208247B1 (fr)
PT (2) PT1544299E (fr)
RS (1) RS50073B (fr)
RU (1) RU2265661C2 (fr)
SK (1) SK287332B6 (fr)
UA (1) UA74146C2 (fr)
WO (1) WO2000075319A1 (fr)
ZA (1) ZA200110068B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
ATE359300T1 (de) 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
WO2004087206A2 (fr) * 2003-03-28 2004-10-14 Regeneron Pharmaceuticals, Inc. Methodes de traitement du diabete par blocage de l'activite induite par le facteur de croissance endotheliale
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1626989A2 (fr) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Methode de traitement du rejet de greffon corneen utilisant des antagonistes du facteur de croissance de l'endothelium vasculaire (vegf)
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
JP4680997B2 (ja) 2004-06-08 2011-05-11 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管新生を阻害するキメラタンパク質およびその利用
AU2005254058A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
WO2006009809A2 (fr) * 2004-06-18 2006-01-26 Regeneron Pharmaceuticals, Inc. Methode d'administration d'inhibiteurs de vegf pour le traitement d'un epanchement pleural malin
EP1771189A2 (fr) 2004-07-30 2007-04-11 Regeneron Pharmaceuticals, Inc. Methodes de traitement du diabete de type i faisant appel au blocage de l'activite induite par le vegf
DK1804835T3 (da) 2004-09-13 2010-10-11 Genzyme Corp Multimere konstruktioner
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (fr) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Methode de traitement de lesion oculaire par l'administration locale d'un inhibiteur de vegf
CA2995971A1 (fr) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Formulations d'antagonistes du facteur vegf
EP1928490B8 (fr) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
JP5489465B2 (ja) † 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
WO2008042236A2 (fr) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions et procédés permettant de diagnostiquer et de traiter le cancer
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
KR101698362B1 (ko) 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
HUE035554T2 (en) 2010-08-06 2018-05-02 Genzyme Corp VEGF antagonist compositions and their uses
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
EP3763379A1 (fr) 2011-01-13 2021-01-13 Regeneron Pharmaceuticals, Inc. Utilisation d'un antagoniste du vegf pour traiter des troubles oculaires angiogéniques
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CA2857168C (fr) * 2011-12-01 2020-10-27 Protevobio, Inc. Inhibiteurs proteiques du complement et des voies du vegf, et procedes d'utilisation associes
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
EP3646880A1 (fr) 2012-05-07 2020-05-06 Allergan, Inc. Procédé de traitement d'amd chez des patients souffrant d'un état réfractaire à la thérapie anti-vegf
WO2014006113A1 (fr) 2012-07-03 2014-01-09 Sanofi Procédé de traitement du cancer par quantités efficaces d'aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
KR20160070164A (ko) 2013-11-05 2016-06-17 알러간, 인코포레이티드 항-vegf darpin으로 눈의 병태를 치료하는 방법
CA2947456C (fr) 2014-05-12 2023-03-14 Formycon Ag Seringue en plastique preremplie contenant un antagoniste de vegf
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
US20170326106A1 (en) 2014-12-11 2017-11-16 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
WO2017065559A1 (fr) 2015-10-15 2017-04-20 (주)알테오젠 Procédé de production de protéine de fusion présentant un domaine fc d'igg
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
BR112018009951A8 (pt) 2015-11-18 2019-02-26 Sio2 Medical Products Inc fármaco oftálmico
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
EP3377101A4 (fr) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Méthodes et compositions de liaison de vegf
KR102261636B1 (ko) 2015-12-03 2021-06-07 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
EP3407868A1 (fr) 2016-01-26 2018-12-05 Formycon AG Formulation liquide d'un antagoniste du vegf
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
WO2018217995A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf
WO2018215580A1 (fr) 2017-05-24 2018-11-29 Formycon Ag Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf
CA3063995A1 (fr) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Conditionnement pharmaceutique sterilisable pour formulations ophtalmiques
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (fr) 2017-07-26 2019-01-31 Formycon Ag Formulation liquide d'un antagoniste du vegf
JP7097433B2 (ja) 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
EP4219695A3 (fr) * 2017-11-27 2024-01-17 4D Molecular Therapeutics Inc. Capsides variantes de virus adéno-associés et leur utilisation pour inhiber l'angiogenèse
PL3716992T3 (pl) 2017-11-30 2022-12-19 Regeneron Pharmaceuticals, Inc. Zastosowanie antagonisty vegf do leczenia angiogennych zaburzeń oka
KR20200097759A (ko) 2017-12-13 2020-08-19 리제너론 파아마슈티컬스, 인크. 크로마토그래피 칼럼 베드 지지체를 관리하기 위한 장치 및 시스템, 및 관련 방법
WO2019147944A1 (fr) * 2018-01-26 2019-08-01 The Regents Of The University Of California Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (fr) 2019-05-16 2020-11-19 Formycon Ag Procédé de réduction de l'oxydation de la méthionine dans des protéines recombinantes
WO2021046070A1 (fr) 2019-09-03 2021-03-11 Amgen Inc. Dispositif d'injection destiné à l'administration de médicament et emballage destiné au dispositif d'injection
US20210077645A1 (en) 2019-09-16 2021-03-18 Amgen Inc. Method for external sterilization of drug delivery device
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
WO2021112925A1 (fr) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Compositions de protéines anti-vegf et procédés de production associés
WO2021113591A1 (fr) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Mini-pièges de vegf et leurs procédés d'utilisation
JP2023514325A (ja) 2020-02-24 2023-04-05 アムジエン・インコーポレーテツド 薬物送達デバイスの外部滅菌中に使用するための容器及びシステム
EP4145456A1 (fr) 2021-09-06 2023-03-08 Bayer AG Prédiction d'un changement relatif à un fluide maculaire
WO2024029876A1 (fr) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 Protéine de fusion modifiée et son utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
HUP0201515A3 (en) 2004-12-28
NO20100656L (no) 2002-02-08
CN103349781B (zh) 2015-04-01
ME00024B (fr) 2010-02-10
JP2003501089A (ja) 2003-01-14
CZ303656B6 (cs) 2013-01-30
ES2237429T3 (es) 2005-08-01
BR0011407A (pt) 2002-04-02
CZ302689B6 (cs) 2011-09-07
DK1544299T3 (da) 2009-03-23
NO330775B1 (no) 2011-07-11
ES2319305T3 (es) 2009-05-06
CN1369009A (zh) 2002-09-11
CZ20014387A3 (cs) 2002-10-16
KR100659477B1 (ko) 2006-12-20
HUP0201515A2 (en) 2002-08-28
PT1183353E (pt) 2005-06-30
UA74146C2 (uk) 2005-11-15
DE60019415T2 (de) 2006-03-09
NO20016036D0 (no) 2001-12-10
SK17522001A3 (sk) 2003-04-01
ATE417928T1 (de) 2009-01-15
YU86901A (sh) 2004-05-12
RS50073B (sr) 2009-01-22
AU2005201365A1 (en) 2005-04-28
LU92195I2 (fr) 2013-07-15
HU230159B1 (hu) 2015-09-28
JP5273746B2 (ja) 2013-08-28
EP1183353A1 (fr) 2002-03-06
ZA200110068B (en) 2002-12-06
CY2013019I1 (el) 2015-11-04
HU229156B1 (en) 2013-09-30
PL352246A1 (en) 2003-08-11
RU2265661C2 (ru) 2005-12-10
CN100523187C (zh) 2009-08-05
MXPA01012630A (es) 2002-07-22
NO332559B1 (no) 2012-10-29
JP2011024595A (ja) 2011-02-10
EP1544299A1 (fr) 2005-06-22
CA2376379A1 (fr) 2000-12-14
EP1183353B1 (fr) 2005-04-13
CN101433715B (zh) 2013-04-17
NO2013010I1 (no) 2013-06-17
EP1544299B1 (fr) 2008-12-17
NO2013010I2 (no) 2013-05-15
CN103349781A (zh) 2013-10-16
IL146890A0 (en) 2002-08-14
BRPI0011407B1 (pt) 2018-09-25
CY1108883T1 (el) 2014-07-02
IL146890A (en) 2008-07-08
HK1132653A1 (en) 2010-03-05
KR20020019070A (ko) 2002-03-09
DE60041159D1 (de) 2009-01-29
NZ515913A (en) 2004-01-30
ATE293164T1 (de) 2005-04-15
LTPA2013009I1 (lt) 2013-06-25
AU2005201365B2 (en) 2007-08-09
SK287332B6 (sk) 2010-07-07
LTC1183353I2 (lt) 2023-02-27
HRP20010908B1 (en) 2006-05-31
MEP3208A (xx) 2010-02-10
CA2376379C (fr) 2007-08-07
HK1043388A1 (en) 2002-09-13
JP4723140B2 (ja) 2011-07-13
NO20016036L (no) 2002-02-08
CN101433715A (zh) 2009-05-20
PT1544299E (pt) 2009-03-18
IL190234A0 (en) 2008-11-03
PL208247B1 (pl) 2011-04-29
BRPI0011407B8 (pt) 2021-05-25
DE60019415D1 (de) 2005-05-19
WO2000075319A1 (fr) 2000-12-14
AU779303B2 (en) 2005-01-13
HK1185798A1 (en) 2014-02-28
HUS1300052I1 (hu) 2016-08-29
BE2013C029I2 (fr) 2019-03-06
HRP20010908A2 (en) 2005-04-30
FR13C0028I1 (fr) 2013-06-14
CY2013019I2 (el) 2015-11-04
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08

Similar Documents

Publication Publication Date Title
FR13C0028I2 (fr) Polypeptides chimeriques modifies a pharmacocinetique amelioree
DE60137876D1 (de) Analoge des Glucagon-ähnlichen Peptids-1
ATE396738T1 (de) Verwendung von glp-2-peptiden
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
ATE323684T1 (de) Verfahren und zusammensetzungen unter verwendung von chinazolinonen
ATE397458T1 (de) Neue heilmittel für krebs
AU4128901A (en) Colored visco-elastic composition
DE60008151D1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
RU95118972A (ru) Способ лечения атеросклеротических макулодистрофий методом прямого лазерофареза
IT1302839B1 (it) Telaio pieghevole a sicurezza incrementata, particolarmente perseggioloni e simili.
ZA200203589B (en) Concomitant drugs for treating glaucoma.